YAP1 and pancreatic adenocarcinoma: In agreement with results from GEPIA, the UALCAN database also demonstrated high levels of YAP1 were shown to be an unfavorable marker for ACC patients (n = 79, p = 0.0015, Figure 2A), LGG patients (n = 511, p = 0.00063, Figure 2B) and PAAD patients (n = 177, p = 0.0015, Figure 2C).